FilingReader Intelligence
Glenmark's Ichnos details next steps following AbbVie licensing agreement
July 10, 2025 at 11:49 AM UTC•By FilingReader AI
Ichnos Glenmark Innovation (IGI), a subsidiary of Glenmark Pharmaceuticals, has announced its global commercialization strategy for ISB 2001, an investigational asset, following an exclusive licensing deal with AbbVie.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
BSE:GLENMARK•Bombay Stock Exchange
News Alerts
Get instant email alerts when Glenmark Pharmaceuticals publishes news
Free account required • Unsubscribe anytime